This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After 2.5 years of continuous medication, there were no changes in various experimental parameters of liver enzymology and cholesterol metabolism.

This product is a new type of anti-microtubule drug. It promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability, and inhibits cell mitosis. In vitro experiments have shown that paclitaxel has a significant radiosensitization effect, which may be to stop cells in the G2 and M phases that are sensitive to radiotherapy. Paclitaxel is a mitotic inhibitor or spindle poison. It has a different mechanism of action from the commonly used chemotherapy drugs. It induces and promotes the assembly of microtubules. Paclitaxel has the effect of polymerizing and stabilizing microtubules, causing rapidly dividing tumor cells to be firmly fixed in the mitotic stage, blocking the replication of cancer cells and causing them to die.

This product is a cephalosporin bactericidal antibiotic that is stable to β-lactamase. It works by blocking the synthesis of bacterial cell wall polymers - peptidoglycan. Because it can quickly penetrate the bacterial cell wall and bind to the target enzyme (penicillin binding protein) with high affinity, it can kill a wide spectrum of Gram-negative and Gram-positive pathogens at low concentrations.

This product is a third-generation cephalosporin antibiotic. It has strong activity against Enterobacteriaceae. The MIC90 for Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Citrobacter fluorescens, indole-positive Proteus, Providencia and Serratia is between 0.12 and 0.25 mg/L. Enterobacter cloacae, Acinetobacter and Pseudomonas aeruginosa are poorly sensitive to this product. It has a strong antibacterial effect on Haemophilus influenzae, Neisseria gonorrhoeae and Neisseria meningitidis, and also has a good effect on hemolytic streptococci and pneumococci. The MIC for Staphylococcus aureus is 2 to 4 mg/L. Methicillin-resistant Staphylococci and enterococci are resistant to this product. Most Bacteroides fragilis are resistant to this product.

Ceftriaxone is a long-acting, broad-spectrum cephalosporin that produces antibacterial effects by inhibiting the synthesis of cell walls. It has a strong bactericidal effect on both Gram-positive and Gram-negative bacteria. It is highly stable to beta-lactamase (including penicillinase and cephalosporinase). In vitro and clinical trials have shown that ceftriaxone sodium has high antibacterial activity against the following Gram-negative bacilli: Escherichia coli, Klebsiella, Proteus mirabilis, indole-positive Proteus, Salmonella, Shigella and other r/Enterobacteriaceae and Haemophilus influenzae; it also has good antibacterial effects on Gram-negative cocci such as meningococci and gonococci; Gram-positive cocci such as pneumococci, Streptococcus pyogenes, Streptococcus viridans, and Streptococcus bovis are all sensitive to this product; it also has a certain antibacterial effect on Staphylococcus aureus, but the antibacterial effect is poorer than that of the above-mentioned Gram-positive cocci. Pseudomonas aeruginosa and Acinetobacter are less sensitive to this product. It also has antibacterial activity against some anaerobic bacteria such as Bacteroides fragilis, Clostridium, and Peptococcus.